Judith Z Goldfinger1, Ajith P Nair2. 1. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Judith.Goldfinger@mountsinai.org. 2. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND: Cardiac remodeling describes the molecular, cellular, and interstitial changes that cause the ventricle to develop pathologic geometry as heart failure progresses. Reverse remodeling, or the healing of a failing heart, leads to improved mortality and quality of life. FINDINGS: Therapies that lead to reverse remodeling include medications such as β-blockers and angiotensin-converting enzyme inhibitors; cardiac resynchronization therapy with biventricular pacing; and mechanical support with left ventricular assist devices. CONCLUSIONS: Further study is needed to better predict which patients will benefit most from these therapies and will then go on to experience reverse remodeling and myocardial recovery.
BACKGROUND: Cardiac remodeling describes the molecular, cellular, and interstitial changes that cause the ventricle to develop pathologic geometry as heart failure progresses. Reverse remodeling, or the healing of a failing heart, leads to improved mortality and quality of life. FINDINGS: Therapies that lead to reverse remodeling include medications such as β-blockers and angiotensin-converting enzyme inhibitors; cardiac resynchronization therapy with biventricular pacing; and mechanical support with left ventricular assist devices. CONCLUSIONS: Further study is needed to better predict which patients will benefit most from these therapies and will then go on to experience reverse remodeling and myocardial recovery.
Authors: Guangyu Wang; Ana Sofia Cruz; Keith Youker; Hernan G Marcos-Abdala; Rajarajan A Thandavarayan; John P Cooke; Guillermo Torre-Amione; Kaifu Chen; Arvind Bhimaraj Journal: Front Genet Date: 2021-01-15 Impact factor: 4.599